Search bioRxiv⌕ Search

bioRxiv · 10.1101/2022.04.14.488421

Validation of the first PGT-whole genome sequencing approach including mitochondrial variants

Abstract

Whole Genome Sequencing (WGS) is used in healthcare and in the clinic, with the notable exception of preimplantation genetic testing (PGT). In PGT, only a few cells are available for sequencing, requiring DNA amplification which reduces data quality, sequence fidelity and sharply limits subsequent clinical impact. Here we demonstrate the first clinical validation of WGS on embryo biopsies using our lab development protocol, opening the door to broad use of WGS in fertility. We find that amplified DNA with comparable sensitivity and specificity to genomic DNA when performing whole genome sequencing assays. DNA amplification on cell lines and donated human embryos had an amplification success rate of >99.9% and 98.2% respectively and accuracy on both was >99.9% on aneuploidy status. GIAB samples (Genome in the Bottle reference NA12878) showed that our amplified DNA was broadly comparable to genomic DNA (99.99% accuracy, 99.99% specificity, 98.0% sensitivity and 98.1% precision). Using our assay, we were able to call variants, detect mitochondrial heteroplasmy, perform high precision screening without access to parental genomes, detect compound heterozygous variants, and score microdups/dels and uniparental disomies (to reduce risk of diseases such as DiGeorge syndrome and Prader-Willi syndrome). Our clinical study suggests that the full spectrum of traditional clinical genome bioinformatics, so far reserved to large samples, can now be performed on embryos before implantation.

Source connections

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Xia, Y., Chandramohan, D., Chertman, W., Bechor, E., Maier, R., Siddiqui, N., Behr, B., Schleede, J.. 2022-04-15. Validation of the first PGT-whole genome sequencing approach including mitochondrial variants. https://doi.org/10.1101/2022.04.14.488421

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Single-cell and spatial multi-omics mapping of human ovarian aging across young and menopausal transition

Ovarian aging is an early feature of human aging with broad consequences for women's health, yet its cellular dynamics across the menopausal transition remain unclear. We integrated single-cell transcriptomic, chromatin accessibility and spatial transcriptomic profiles across young, menopausal-transition and postmenopausal human ovaries. Granulosa cells (GCs) exhibited the most pronounced age-associated transcriptional remodelling. The menopausal transition was characterized by reduced DNA-repair activity and elevated stress-response programs in GCs, alongside broader changes in hormone-response and steroid-metabolic programs during ovarian aging. Integrated regulatory analyses implicated HEYL, a GC-enriched transcription factor, with reduced accessibility at a putative regulatory element during aging. Genetic analyses associated HEYL and its predicted upstream regulators with age at natural menopause, while spatial mapping revealed enrichment of menopause-associated genetic signals in GC-rich regions. HEYL depletion increased senescence-associated phenotypes in human granulosa-like cells and primary mouse GCs, whereas overexpression attenuated oxidative-stress-induced senescence. Perturbation of its orthologue Hey produced consistent effects in Drosophila ovaries. Together, our atlas reveals stage-associated granulosa-cell remodeling and implicates HEYL in ovarian aging.

genomics↗

Identification of JMJD1C as a key mediator of fibroblast remodelling in human AF by single-nucleus multi-omics

Atrial fibrillation (AF) is the most prevalent arrhythmia, accounting for up to 15% of arrhythmias in the elderly. Atrial enlargement associated with fibrotic and hypertrophic remodelling, termed atrial myopathy (AM), is considered a precursor to AF development. The mechanisms underlying the development of AM and its progression to AF remain incompletely resolved. To identify the unique and combined contributions of the major cellular mediators of AM and AF, we combine single-nucleus transcriptomics of human left and right atrial appendages (LAA and RAA) with paired RNA and chromatin-accessibility profiling of 20 LAA samples. We validate these findings through histological and functional studies in primary human cardiac fibroblasts (HCFs). Patients were stratified according to the presence of AF and AM (identified by left atrial volume dimensions; LAVI, Hi and Lo), generating Hi-AF, Hi-SR, Lo-AF and Lo-SR groups that separate AF-associated from structural-remodelling-associated alterations. Across 75,654 qualified nuclei, AF was associated with chamber-dependent shifts in cellular composition and gene expression, with extracellular matrix (ECM) and TGF-beta programmes prominent in LAA. Multiome analysis identified a stressed atrial cardiomyocyte (aCM4) state expressing natriuretic peptide A (NPPA) and natriuretic peptide B (NPPB), with altered cis-regulatory connectivity, and an inflammatory fibroblast (PTGDS+ FB) state characterised by IL-6 expression and matrix- and TGF-beta-associated programmes. Enhancer-driven network analysis identified GLIS3, TWIST2 and TBX20 as regulators of FB state transitions. The histone demethylase JMJD1C was enriched in PTGDS+ FB and induced by TGF-beta; its depletion attenuated alpha-smooth-muscle-actin (alpha-SMA) accumulation and reprogrammed TGF-beta-responsive transcription. Ligand-receptor analysis further predicted macrophage-to-FB TGF-beta signalling, showing the contribution of macrophages to the atrial inflammatory environment. These data define discrete aspects of rhythm- and structure-associated remodelling of human atrial tissue and identify a candidate macrophage-TGF-beta-JMJD1C-FB interaction for potential therapeutic development.

genomics↗

Midkine and the immunosuppressive tumor microenvironment in pancreatic ductal adenocarcinoma: evidence from Mendelian randomization, multi-omics factor analysis, and single-cell transcriptomics

Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, in part because its tumor microenvironment actively suppresses antitumor immunity. Midkine (MDK) is a secreted heparin-binding growth factor that is overexpressed in a majority of PDAC tumors, but whether it contributes causally to disease risk and through which cell types it acts have not been firmly established. We combined cis-eQTL Mendelian randomization (GTEx pancreas, n = 328 donors; FinnGen PDAC, 1,252 cases) with multi-omics factor analysis (MOFA) of TCGA-PAAD tumors (n = 149), single-sample gene set enrichment analysis (ssGSEA), cross-species single-cell RNA sequencing, and DepMap CRISPR dependency screening. Mendelian randomization identified MDK as the only gene passing false discovery rate correction for PDAC risk (inverse-variance-weighted odds ratio 1.51, 95% CI 1.19-1.91, p = 6.7 x 10??; FDR = 0.008), with concordant direction across five methods and five independent GWAS. MDK was overexpressed in tumors relative to adjacent normal tissue in an independent cohort (GSE62452, n = 130, p = 5 x 10??), and high expression was associated with shorter overall survival (10.2 versus 21.1 months, p = 0.023). In the MOFA decomposition, MDK localized to a factor characterized by tertiary lymphoid structure gene expression but negative correlation with dendritic cells and macrophages, a pattern consistent with immune exclusion. Single-cell analysis and published functional studies indicated that MDK is produced by cancer-associated fibroblasts and endothelial cells rather than by tumor epithelium, and DepMap data confirmed that MDK is not a cell-autonomous fitness gene. Collectively, these results support a model in which MDK acts through the stromal-immune compartment rather than through tumor cell-intrinsic mechanisms, and raise the possibility that MDK blockade could restore antitumor immunity in PDAC.

genomics↗